{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:02:35Z","timestamp":1785268955729,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,19]]},"DOI":"10.7759\/cureus.54487","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T01:36:30Z","timestamp":1708392990000},"source":"Crossref","is-referenced-by-count":2,"title":["Nephrological Detrimental Impacts Resulting From Novel Immunotherapy Drugs Used in the Treatment of Cancer: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Amisha","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kainaat","family":"Shergill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusalik","family":"Boppana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiela E","family":"Almansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloni","family":"Bakkannavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmna","family":"Faheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuheen Sankar","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Cancer Research. 30 facts about immunotherapy. Accessed: August 24, 2023: https:\/\/www.cancerresearch.org\/immunotherapy-facts."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the immune system: the history and background of immunotherapy","volume":"35","author":"Abbott M","year":"2019","unstructured":"Abbott M, Ustoyev Y. Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs. 2019, 35:150923. 10.1016\/j.soncn.2019.08.002","journal-title":"Semin Oncol Nurs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy","volume":"10","author":"Dobosz P","year":"2019","unstructured":"Dobosz P, Dzieci\u0105tkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019, 10:2965. 10.3389\/fimmu.2019.02965","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.574271","article-title":"The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?","volume":"11","author":"Franzin R","year":"2020","unstructured":"Franzin R, Netti GS, Spadaccino F, et al.. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?. Front Immunol. 2020, 11:574271. 10.3389\/fimmu.2020.574271","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.03.024","article-title":"Mechanisms of immunotherapy","volume":"113","author":"Till SJ","year":"2004","unstructured":"Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004, 113:1025-34; quiz 1035. 10.1016\/j.jaci.2004.03.024","journal-title":"J Allergy Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley RS","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019, 18:175-96. 10.1038\/s41573-018-0006-z","journal-title":"Nat Rev Drug Discov"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.04.001","article-title":"Utilizing chemokines in cancer immunotherapy","volume":"8","author":"M\u00e4rkl F","year":"2022","unstructured":"M\u00e4rkl F, Huynh D, Endres S, Kobold S. Utilizing chemokines in cancer immunotherapy. Trends Cancer. 2022, 8:670-82. 10.1016\/j.trecan.2022.04.001","journal-title":"Trends Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang Y","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020, 17:807-21. 10.1038\/s41423-020-0488-6","journal-title":"Cell Mol Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174086","article-title":"Adverse renal effects of anticancer immunotherapy: a review","volume":"14","author":"Bor\u00f3wka M","year":"2022","unstructured":"Bor\u00f3wka M, \u0141\u0105cki-Zynzeling S, Nicze M, Kozak S, Chudek J. Adverse renal effects of anticancer immunotherapy: a review. Cancers (Basel). 2022, 14:10.3390\/cancers14174086","journal-title":"Cancers (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy LB","year":"2020","unstructured":"Kennedy LB, Salama AK. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020, 70:86-104. 10.3322\/caac.21596","journal-title":"CA Cancer J Clin"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.05.010","article-title":"Integrative approaches to cancer immunotherapy","volume":"5","author":"Szeto GL","year":"2019","unstructured":"Szeto GL, Finley SD. Integrative approaches to cancer immunotherapy. Trends Cancer. 2019, 5:400-10. 10.1016\/j.trecan.2019.05.010","journal-title":"Trends Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cells11243991","article-title":"Acute kidney injury in cancer immunotherapy recipients","volume":"11","author":"Joseph A","year":"2022","unstructured":"Joseph A, Lafarge A, Azoulay E, Zafrani L. Acute kidney injury in cancer immunotherapy recipients. Cells. 2022, 11:10.3390\/cells11243991","journal-title":"Cells"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta S","year":"2021","unstructured":"Gupta S, Short SA, Sise ME, et al.. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021, 9:10.1136\/jitc-2021-003467","journal-title":"J Immunother Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa137","article-title":"Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort","volume":"36","author":"Stein C","year":"2021","unstructured":"Stein C, Burtey S, Mancini J, et al.. Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol Dial Transplant. 2021, 36:1664-74. 10.1093\/ndt\/gfaa137","journal-title":"Nephrol Dial Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz A","year":"2020","unstructured":"Meraz-Mu\u00f1oz A, Amir E, Ng P, et al.. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer. 2020, 8:10.1136\/jitc-2019-000467","journal-title":"J Immunother Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar FB","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG, et al.. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020, 31:435-46. 10.1681\/ASN.2019070676","journal-title":"J Am Soc Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03202-5","article-title":"Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report","volume":"24","author":"Yang Z","year":"2023","unstructured":"Yang Z, Xu H, Gou S, Wu H, Hu Z. Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report. BMC Nephrol. 2023, 24:145. 10.1186\/s12882-023-03202-5","journal-title":"BMC Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15358","article-title":"Immunotherapy-induced acute tubulointerstitial nephritis","volume":"13","author":"Parza K","year":"2021","unstructured":"Parza K, Dao K, Patel P, Scibelli N, Mangano A, Gondal M. Immunotherapy-induced acute tubulointerstitial nephritis. Cureus. 2021, 13:e15358. 10.7759\/cureus.15358","journal-title":"Cureus"},{"key":"ref19","article-title":"Immunotherapy-induced glomerulonephritis: whodunit?","volume":"5","author":"Benes B","year":"2023","unstructured":"Benes B. Immunotherapy-induced glomerulonephritis: whodunit?. J Grad Med Educ. 2023, 5:39.","journal-title":"J Grad Med Educ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.34172\/npj.2021.22","article-title":"Immune-related adverse kidney events by immune checkpoint inhibitors; a narrative review on current studies","volume":"10","author":"Sadighpour T","year":"2021","unstructured":"Sadighpour T, Cagnazzo C, Alimohammadi S, Emami A, Khayyat A, EsmaeilPour MA. Immune-related adverse kidney events by immune checkpoint inhibitors; a narrative review on current studies. J Nephropharmacol. 2021, 10: e22-e22. 10.34172\/npj.2021.22","journal-title":"J Nephropharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.906565","article-title":"Immunotherapy and the spectrum of kidney disease: should we individualize the treatment?","volume":"9","author":"Bermejo S","year":"2022","unstructured":"Bermejo S, Bolufer M, Riveiro-Barciela M, Soler MJ. Immunotherapy and the spectrum of kidney disease: should we individualize the treatment?. Front Med (Lausanne). 2022, 9:906565. 10.3389\/fmed.2022.906565","journal-title":"Front Med (Lausanne)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.14671121","article-title":"Electrolyte and acid-base disorders associated with cancer immunotherapy","volume":"17","author":"Uppal NN","year":"2022","unstructured":"Uppal NN, Workeneh BT, Rondon-Berrios H, Jhaveri KD. Electrolyte and acid-base disorders associated with cancer immunotherapy. Clin J Am Soc Nephrol. 2022, 17:922-33. 10.2215\/CJN.14671121","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2021.07.006","article-title":"Immunotherapy-related acute kidney injury","volume":"28","author":"Manohar S","year":"2021","unstructured":"Manohar S, Jhaveri KD, Perazella MA. Immunotherapy-related acute kidney injury. Adv Chronic Kidney Dis. 2021, 28:429-437.e1. 10.1053\/j.ackd.2021.07.006","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898811","article-title":"Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma","volume":"13","author":"Ratanasrimetha P","year":"2022","unstructured":"Ratanasrimetha P, Reddy VD, Kala J, Tchakarov A, Glass WF, Msaouel P, Lin JS. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma. Front Immunol. 2022, 13:898811. 10.3389\/fimmu.2022.898811","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1918-23","article-title":"Pembrolizumab-induced acute tubulointerstitial nephritis accompanying Fanconi syndrome and type 1 renal tubular acidosis","volume":"63","author":"Fujioka H","year":"2024","unstructured":"Fujioka H, Kakeshita K, Imamura T, et al.. Pembrolizumab-induced acute tubulointerstitial nephritis accompanying Fanconi syndrome and type 1 renal tubular acidosis. Intern Med. 2024, 63:533-9. 10.2169\/internalmedicine.1918-23","journal-title":"Intern Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094618","article-title":"Nephrotoxicity as a complication of chemotherapy and immunotherapy in the treatment of colorectal cancer, melanoma and non-small cell lung cancer","volume":"22","author":"Jagie\u0142a J","year":"2021","unstructured":"Jagie\u0142a J, Bartnicki P, Rysz J. Nephrotoxicity as a complication of chemotherapy and immunotherapy in the treatment of colorectal cancer, melanoma and non-small cell lung cancer. Int J Mol Sci. 2021, 22:10.3390\/ijms22094618","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/227348-nephrological-detrimental-impacts-resulting-from-novel-immunotherapy-drugs-used-in-the-treatment-of-cancer-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T01:36:35Z","timestamp":1708392995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/227348-nephrological-detrimental-impacts-resulting-from-novel-immunotherapy-drugs-used-in-the-treatment-of-cancer-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.54487","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,19]]}}}